We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure [email protected]
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter deals with epidemiology, pathology, clinical patterns and diagnosis of multiple sclerosis (MS). It also discusses the treatment options for MS and provides a brief account of other acquired demyelinating diseases. MS is characterized clinically by two major patterns: relapsing-remitting neurological deficits and a progressive neurological deficit. The key diagnostic investigation in MS is magnetic resonance imaging (MRI) scanning, which is abnormal in 95 % of patients. The relationship of seizures to MS activity has been explored and most studies report that about one-third of seizures occur in the context of an acute relapse of MS, sometimes taking the form of focal status epilepticus, usually focal motor status. The treatment of multiple sclerosis falls into three broad categories: symptomatic treatment of the neurological complications of MS, treatment of acute relapses with high-dose corticosteroids, and the use of disease- modifying therapies, including beta-interferon, glatarimer acetate, natalizumab, and mitoxantrone.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.